✦ LIBER ✦

SORAFENIB IN ADVANCED RENAL CELL CARCINOMA (RCC): SURVIVAL AND BIOMARKER RESULTS FROM A PHASE III TRIAL

✍ Scribed by R. Bukowski; D. Heng; T. Eisen; C. Szczylik; W.M. Stadler; C. Porta; R. Simantov; M. Shan; J. Elting; C. Pena; B. Escudier

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

857 RANDOMIZED PHASE III TRIAL OF SORAFE

✍ T. Eisen; R. Bukowski; M. Staehler; C. Szczylik; S. Oudard; W. Stadler; R. Siman 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 328 KB

RANDOMISED PHASE III TRIAL OF THE MULTIK

✍ Escudier, B.; Szczylik, C.; Eisen, T.; Oudard, S.; Stadler, W.M.; Schwartz, B.; 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 58 KB

7130 Efficacy and safety of sorafenib in

✍ Bukowski, R.; Eisen, T.E.; Stadler, W.S.; Szczylik, C.S.; Oudard, O.S.; Siebels, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

A phase I/II trial of sorafenib and infl

✍ Larkin, J M G; Ferguson, T R; Pickering, L M; Edmonds, K; James, M G; Thomas, K; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 226 KB

794 ORAL Randomized Phase III trial of t

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Axitinib versus sorafenib as second-line

✍ Motzer, Robert J; Escudier, Bernard; Tomczak, Piotr; Hutson, Thomas E; Michaelso 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 316 KB